Coexpression of fragile histidine triad and c-kit is relevant for prediction of survival in patients with small cell lung cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 11, 2006, Pages 2232-2238

  Rehfeld, Nina ^a   Geddert, Helene ^a   Atamna, Abedelsalam ^a   Gabbert, Helmut E ^a   Steidl, Ulrich ^b   Fenk, Roland ^a   Kronenwett, Ralf ^a   Haas, Rainer ^a   Rohr, Ulrich Peter ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b HARVARD STEM CELL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FRAGILE HISTIDINE TRIAD PROTEIN; LACTATE DEHYDROGENASE; STEM CELL FACTOR;

ADULT; AGED; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IRRADIATION; KAPLAN MEIER METHOD; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME;

ACID ANHYDRIDE HYDROLASES; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SMALL CELL; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-KIT; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33845284534     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-0342     Document Type: Article

References (35)

1. Ohta M, Inoue H, Cotticelli MG, et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 1996;84:587-97.
2. Pace HC, Garrison PN, Robinson AK, et al. Genetic, biochemical, and crystallographic characterization of FHIT-substrate complexes as the active signaling form of Fhit. Proc Natl Acad Sci U S A 1998;95:5484-9.
3. Askari MR, Vo-Dinh T. Implication of mitochondrial involvement in apoptotic activity of fragile histidine triad gene: application of synchronous luminescence spectroscopy. Biopolymers 2004;73:510-23.
4. Sard L, Accornero P, Tornielli S, et al. The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc Natl Acad Sci U S A 1999;96:8489-92.
5. Wistuba II, Behrens C, Virmani AK, et al. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res 2000;60:1949-60.
6. Wistuba II, Gazdar AF, Minna JD. Molecular genetics of small cell lung carcinoma. Semin Oncol 2001;28:3-13.
7. Kim JS, Kim JW, Han J, Shim YM, Park J, Kim DH. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer. Cancer Res 2006;66:4049-54.
8. Wali A, Srinivasan R, Shabnam MS, Majumdar S, Joshi K, Behera D. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation. Mol Cancer Res 2006;4:93-9.
9. Pylkkanen L, Wolff H, Stjernvall T, et al. Reduced Fhit protein expression and loss of heterozygosity at FHIT gene in tumors from smoking and asbestos-exposed lung cancer patients. Int J Oncol 2002;20:285-90.
10. Otterson GA, Xiao GH, Geradts J, et al. Protein expression and functional analysis of FHIT gene in human tumor cells. J Natl Cancer Inst 1998;90:426-32.
11. Sozzi G, Tornielli S, Tagliabue E, et al. Absence of Fhit protein in primary lung tumors and cell lines with FHIT gene abnormalities. Cancer Res 1997;57:5207-12.
12. Rohr UP, Rehfeld N, Geddert H, et al. Prognostic relevance of Fragile Histidine Triad Protein Expression in Patients with Small Cell Lung Cancer. Clin Cancer Res 2005;11:180-5.
13. Entz-Werle N, Marcellin L, Gaub MP, et al. Prognostic significance of allelic imbalance at the c-kit gene locus and c-kit overexpression by immunohistochemistry in pediatric osteosarcomas. J Clin Oncol 2005;23:2248-55.
14. Hida T, Ueda R, Sekido Y, et al. Ectopic expression of c-kit in small-cell lung cancer. Int J Cancer Suppl 1994;8:108-9.
15. Papadimitriou CA, Topp MS, Serve H, et al. Recombinant human stem cell factor does exert minor stimulation of growth in small cell lung cancer and melanoma cell lines. Eur J Cancer 1995;31A:2371-8.
16. Krystal GW, Hines SJ, Organ CP. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res 1996;56:370-6.
17. Sekido Y, Takahashi T, Ueda R, et al. Recombinant human stem cell factor mediates chemotaxis of small-cell lung cancer cell lines aberrantly expressing the c-kit protooncogene. Cancer Res 1993;53:1709-14.
18. Yamanishi Y, Maeda H, Hiyama K, Ishioka S, Yamakido M. Specific growth inhibition of small-cell lung cancer cells by adenovirus vector expressing antisense c-kit transcript. Jpn J Cancer Res 1996;87:534-42.
19. Potti A, Moazzam N, Ramar K, Hanekom DS, Kargas S, Koch M. CD117 (c-KIT) overexpression in patients with extensive-stage small-cell lung carcinoma. Ann Oncol 2003;14:894-7.
20. Micke P, Basrai M, Faldum A, et al. Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications. Clin Cancer Res 2003;9:188-94.
21. Naeem M, Dahiya M, Clark JI, Creech SD, Alkan S. Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosis. Hum Pathol 2002;33:1182-7.
22. Rohr UP, Rehfeld N, Pflugfelder L, et al. Expression of the tyrosine kinase c-kit is an independent prognostic factor in patients with small cell lung cancer. Int J Cancer 2004;111:259-63.
23. Sobin LH, Wittekind CH. TNM classification of malignant tumors, 6th ed. New York: Wiley-Liss. Inc.; 2002. (published by UICC).
24. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-7.
25. Ramp U, Caliskan E, Ebert T, et al. FHIT expression in clear cell renal carcinomas: versatility of protein levels and correlation with survival. J Pathol 2002;196:430-6.
26. Zanesi N, Fidanza V, Fong LY, et al. The tumor spectrum in FHIT-deficient mice. Proc Natl Acad Sci U S A 2001;98:10250-83.
27. Ji L, Fang B, Yen N, Fong K, Minna JD, Roth JA. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res 1999;59:3333-9.
28. Toledo G, Sola JJ, Lozano MD, Soria E, Pardo J. Loss of FHIT protein expression is related to high proliferation, low apoptosis, and worse prognosis in non-small-cell lung cancer. Mod Pathol 2004;17:440-8.
29. Tomizawa Y, Nakajima T, Kohno T, Saito R, Yamaguchi N, Yokota J. Clinicopathological significance of Fhit protein expression in stage I non-small cell lung carcinoma. Cancer Res 1998;58:5478-83.
30. Hirota S. Gastrointestinal stromal tumors: their origin and cause. Int J Clin Oncol 2001;6:1-5.
31. Beghini A, Larizza L, Cairoli R, Morra E. C-kit activating mutations and mast cell-proliferation in human leukemia. Blood 1998;92:701-2.
32. Nakata Y, Kimura A, Katoh O, et al. C-kit point mutation of extracellular domain in patients with myeloproliferative disorders. Br J Haematol 1995;91:661-3.
33. Hibi K, Takahashi T, Sekido Y, et al. Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene 1991;6:2291-6.
34. Tamberi S, Longo L, Rossi G, et al. Loss of c-kit expression after chemotherapy in small cell lung cancer: therapeutic implications [abstract 2607]. Proc ASCO 2003;22.
35. Dy GK, Miller AA, Mandrekar SJ, et al. A phase II trials of imatinib (ST1571) in patients with c-kit-expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol 2005;16:1811-6.